Activation of Growth Factor Receptors in Esophageal Cancer—Implications for Therapy
Authors:
Open Access
- 1 October 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (10) , 1165-1177
Abstract
Esophageal cancer is a highly aggressive disease and is the seventh most common cause of cancer-related death in the western world. Worldwide, it ranks as the sixth most frequent cause of cancer death. Despite advances in surgical techniques and treatment, the prognosis of esophageal cancer remains poor, with very few long-term survivors. The need for novel strategies to detect esophageal cancer earlier and to improve current therapy is urgent. It is well established that growth factors and growth factor receptor–mediated signaling pathways are important components of the transformation process in many forms of cancer, including esophageal cancer. With the recent advances in drug development, there are emerging possibilities to use growth factor signal transduction pathways in targeted therapy. This review provides a summary of the role of growth factors and their receptors in esophageal cancer and discusses their potential roles as biomarkers and as targets in therapy.Keywords
This publication has 102 references indexed in Scilit:
- HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survivalDiseases of the Esophagus, 2006
- Antitumor effect of gefitinib (‘Iressa’) on esophageal squamous cell carcinoma cell lines in vitro and in vivoCancer Letters, 2005
- ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor‐tyrosine kinase inhibitor, enhances the anti‐cancer effects of TRAIL in human esophageal squamous cell carcinomaFEBS Letters, 2005
- ERBB2 Amplifications in Esophageal AdenocarcinomaThe Annals of Thoracic Surgery, 2004
- Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1Journal of Gastroenterology, 2002
- Prognostic Value of Laurén Classification and c-erbB-2 Oncogene Overexpression in Adenocarcinoma of the Esophagus and Gastroesophageal JunctionAnnals of Surgical Oncology, 1999
- Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cellsCancer Letters, 1996
- Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor ?Journal of Cancer Research and Clinical Oncology, 1993